Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics, a biotech company developing weight loss drug candidates, could potentially reach $100 per share according to Wall Street analysts, though it currently trades around $27. The company's lead candidate VK2735, a dual GLP-1/GIP receptor agonist, is in late-stage trials and would be the first dual GLP-1/GIP drug available in oral format. Upcoming catalysts include maintenance dosing study data in Q3 and a phase 3 trial launch for the oral version in Q4. While a jump to $100 would require a 200%+ increase, positive trial results and market momentum could drive the stock higher in coming quarters.